{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"Grades II-IV acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Grades III-IV acute GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"Percentage of participants who developed grades II-IV and grades III-IV acute GVHD. Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).","groups":[{"description":"Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.","id":"OG000","title":"Bone Marrow Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. GVHD data was collected on 15 additional participants for a total of 132. GVHD data was not collected on the remaining 10 participants.","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD)","type":"PRIMARY","unitOfMeasure":"Participants"}